XM does not provide services to residents of the United States of America.

J&J in talks with holdouts to $6.5 billion talc settlement



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>J&J in talks with holdouts to $6.5 billion talc settlement</title></head><body>

By Dietrich Knauth and Mike Spector

NEW YORK, Aug 23 (Reuters) -Johnson & Johnson JNJ.N said on Friday it is negotiating with plaintiffs' lawyers who have opposed the company's proposed settlement of lawsuits alleging its baby powder and other talc products caused cancer, seeking to eliminate holdouts to the deal.

J&J has announced plans to finalize a $6.48 billion global settlement through the bankruptcy of a subsidiary company, after earlier efforts were rebuffed twice by federal courts.

J&J says the majority of claimants support its settlement offer. But it has paused a vote count for a short time so that it can gather additional votes from plaintiffs who have until recently opposed the deal.

"We have agreed to a short extension of the certification timeline," said Erik Haas, J&J's worldwide vice president of litigation, in a statement. "This will allow these plaintiffs' attorneys time to speak to their claimants to now consider supporting the plan."

A lawyer at Beasley Allen, a law firm that has led opposition to J&J's proposed bankruptcy settlement, did not immediately respond to a request for comment.

J&J plans to place a subsidiary into bankruptcy if it gets at least 75% of the talc claimants to vote for its settlement proposal.

The bankruptcy settlement would end all talc lawsuits alleging that J&J products cause ovarian cancer, and it would prevent similar cases from being filed in the future.

J&J faces lawsuits from more than 62,000 plaintiffs alleging that its baby powder and other talc products were contaminated with asbestos and caused ovarian and other cancers. J&J denies the allegations and has said that its products are safe, do not contain asbestos and do not cause cancer.

The current proposed settlement focuses on ovarian cancer claims, building on the company's previous settlement of most lawsuits alleging that its talc caused mesothelioma, a deadly cancer linked to asbestos exposure.

By using a subsidiary's bankruptcy to file for bankruptcy, J&J seeks to force all plaintiffs into one settlement – without requiring J&J itself to file bankruptcy.

Bankruptcy judges can enforce global settlements that permanently halt all related lawsuits and forbid new ones.

Outside of bankruptcy, any settlement J&J reached with some clients would still leave holdouts or future plaintiffs with the right to sue – and leave the company exposed to potential multibillion-dollar verdicts that encouraged it to pursue a bankruptcy settlement in the first place.

J&J has prevailed in many of the ovarian cases tried to date, but the litigation has also resulted in some large verdicts for plaintiffs, including a $2.12 billion award in favor of 22 women who blamed their ovarian cancer on asbestos in J&J talc.



Reporting by Dietrich Knauth, Editing by Alexia Garamfalvi and Marguerita Choy

</body></html>

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.